JP7134541B1 - キサンチンオキシダーゼ阻害用医薬組成物及び食品組成物 - Google Patents
キサンチンオキシダーゼ阻害用医薬組成物及び食品組成物 Download PDFInfo
- Publication number
- JP7134541B1 JP7134541B1 JP2022087817A JP2022087817A JP7134541B1 JP 7134541 B1 JP7134541 B1 JP 7134541B1 JP 2022087817 A JP2022087817 A JP 2022087817A JP 2022087817 A JP2022087817 A JP 2022087817A JP 7134541 B1 JP7134541 B1 JP 7134541B1
- Authority
- JP
- Japan
- Prior art keywords
- xanthine oxidase
- food
- pharmaceutical composition
- acetyl
- benzylpyrrolidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010093894 Xanthine oxidase Proteins 0.000 title claims abstract description 38
- 102100033220 Xanthine oxidase Human genes 0.000 title claims abstract description 38
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 27
- 235000013305 food Nutrition 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- FIFRJJLOOYYYOZ-UHFFFAOYSA-N 5-acetyl-1-benzylpyrrolidin-2-one Chemical compound CC(=O)C1CCC(=O)N1CC1=CC=CC=C1 FIFRJJLOOYYYOZ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical group O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 18
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 14
- 238000002835 absorbance Methods 0.000 description 13
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 10
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 9
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 9
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 229940116269 uric acid Drugs 0.000 description 9
- -1 etc.) Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 229940075420 xanthine Drugs 0.000 description 7
- 239000008187 granular material Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000006057 Non-nutritive feed additive Substances 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000007910 chewable tablet Substances 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 239000004373 Pullulan Substances 0.000 description 3
- 229920001218 Pullulan Polymers 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000001727 glucose Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000014593 oils and fats Nutrition 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 235000019423 pullulan Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000021552 granulated sugar Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- NMQBDPGEPWYYIL-UHFFFAOYSA-N 3-acetyl-1-benzylpyrrolidin-2-one Chemical compound O=C1C(C(=O)C)CCN1CC1=CC=CC=C1 NMQBDPGEPWYYIL-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010028311 Muscle hypertrophy Diseases 0.000 description 1
- 101150098694 PDE5A gene Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000012042 muscle hypertrophy Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
キサンチンオキシダーゼ活性測定はヒポキサンチン又はキサンチンを基質としてキサンチンオキシダーゼ添加によって最終的に生成する尿酸量を290nmの吸光度を測定することによって評価した。コントロールとして5-アセチル-1-ベンジルピロリジン-2-オンを添加しない場合を100%として、5-アセチル-1-ベンジルピロリジン-2-オン存在下での吸光度の上昇抑制率を求めることにより5-アセチル-1-ベンジルピロリジン-2-オンのキサンチンオキシダーゼ阻害効果があるか否かを確認した。
1)検体の調製
5-アセチル-1-ベンジルピロリジン-2-オンは、1%DMSO(Dimethyl Sulfoxide:ジメチ
ルスルホキシド)溶液(リン酸緩衝液)に溶解して調製した。
さらに1%DMSOで段階希釈し、試験用の濃度系列のサンプル液を調製した(15mg/mL~90mg/mL)。
2)―1 ヒポキサンチンを基質としたキサンチンオキシダーゼ阻害活性の測定
各濃度の被験物質50μL、100mMリン酸緩衝液35μL、0.1units/mLのキサンチンオキシダーゼ(Xanthine Oxidase from bovine milk:シグマアルドリッチ社製)30μLを混和し、37℃で15分間インキュベートした。さらに0.75 mMヒポキサンチンを60μL添加し、37℃で30分間反応させた。
次いで1N塩酸25μLを添加して、反応を停止させた。この時生成した尿酸を、プレートリーダーにて290nmにおける吸光度を測定した。
2)-2 キサンチンを基質としたキサンチンオキシダーゼ阻害活性の測定
各濃度の被験物質50μL、50mMリン酸緩衝液35μL、0.1units/mLのキサンチンオキシダーゼ(Xanthine Oxidase from bovine milk:シグマアルドリッチ社製)30μLを混和し、25℃で15分間インキュベートした。さらに1.5mMキサンチンを60μL添加し、25℃で30分間反応させた。
次いで1N塩酸25μLを添加して、反応を停止させた。この時生成した尿酸を、プレートリーダーにて290nmにおける吸光度を測定した。
3)解析
測定した反応液中の290nmにおける吸光度を用いて、キサンチンオキシダーゼ阻害率(%)
を以下計算式により求め、50%阻害率(IC50)に相当する濃度を得た。
阻害率(%)=100-{(D吸光度-C吸光度)/(B吸光度-A吸光度)×100}
A:被験物質無添加、酵素添加での290nmにおける吸光度
B:被験物質無添加、酵素無添加での290nmにおける吸光度
C:被験物質添加、酵素添加での290nmにおける吸光度
D:被験物質添加、酵素無添加での290nmにおける吸光度
5-アセチル-1-ベンジルピロリジン-2-オンのIC50はヒポキサンチンを基質とした場合は18.8mg/mL、キサンチンを基質とした場合は11.5mg/mLであった。
この結果から5-アセチル-1-ベンジルピロリジン-2-オンはキサンチンオキシダーゼ阻害
効果を有することを確認した。
Claims (2)
- 5-アセチル-1-ベンジルピロリジン-2-オンを有効成分として含有してなるキサンチンオキシダーゼ阻害用医薬組成物。
- 5-アセチル-1-ベンジルピロリジン-2-オンを有効成分として含有してなるキサンチンオキシダーゼ阻害用食品組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022087817A JP7134541B1 (ja) | 2022-05-30 | 2022-05-30 | キサンチンオキシダーゼ阻害用医薬組成物及び食品組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022087817A JP7134541B1 (ja) | 2022-05-30 | 2022-05-30 | キサンチンオキシダーゼ阻害用医薬組成物及び食品組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP7134541B1 true JP7134541B1 (ja) | 2022-09-12 |
JP2023175394A JP2023175394A (ja) | 2023-12-12 |
Family
ID=83229686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022087817A Active JP7134541B1 (ja) | 2022-05-30 | 2022-05-30 | キサンチンオキシダーゼ阻害用医薬組成物及び食品組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7134541B1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7253301B1 (ja) * | 2023-01-27 | 2023-04-06 | Towa Corporation 株式会社 | 5-アミノレブリン酸産生促進用医薬組成物及び食品組成物 |
JP7311218B1 (ja) * | 2023-05-30 | 2023-07-19 | Towa Corporation 株式会社 | アポリポタンパク質e遺伝子発現抑制用医薬組成物及び食品組成物 |
JP7316017B1 (ja) * | 2023-05-30 | 2023-07-27 | Towa Corporation 株式会社 | セレノプロテインo遺伝子発現亢進用医薬組成物及び食品組成物 |
JP7320897B1 (ja) * | 2023-05-10 | 2023-08-04 | Towa Corporation 株式会社 | 脱共役タンパク2遺伝子発現亢進用医薬組成物及び食品組成物 |
JP7356203B1 (ja) | 2023-08-03 | 2023-10-04 | Towa Corporation 株式会社 | WD and tetratricopeptide repeats 1遺伝子発現亢進用医薬組成物及び食品組成物 |
JP7397541B1 (ja) * | 2023-05-10 | 2023-12-13 | Towa Corporation 株式会社 | Nadh-ユビキノン酸化還元酵素サブユニット6遺伝子発現亢進用医薬組成物及び食品組成物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6537689B1 (ja) | 2018-10-26 | 2019-07-03 | Towa Corporation 株式会社 | エストラジオール産生促進用医薬組成物及び食品組成物 |
JP6578046B1 (ja) | 2018-08-23 | 2019-09-18 | Towa Corporation 株式会社 | Pde5阻害用医薬組成物及びpde5阻害用食品組成物 |
JP6962630B1 (ja) | 2021-04-01 | 2021-11-05 | Towa Corporation 株式会社 | 筋肥大促進用医薬組成物及び食品組成物 |
-
2022
- 2022-05-30 JP JP2022087817A patent/JP7134541B1/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6578046B1 (ja) | 2018-08-23 | 2019-09-18 | Towa Corporation 株式会社 | Pde5阻害用医薬組成物及びpde5阻害用食品組成物 |
JP6537689B1 (ja) | 2018-10-26 | 2019-07-03 | Towa Corporation 株式会社 | エストラジオール産生促進用医薬組成物及び食品組成物 |
JP6962630B1 (ja) | 2021-04-01 | 2021-11-05 | Towa Corporation 株式会社 | 筋肥大促進用医薬組成物及び食品組成物 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7253301B1 (ja) * | 2023-01-27 | 2023-04-06 | Towa Corporation 株式会社 | 5-アミノレブリン酸産生促進用医薬組成物及び食品組成物 |
JP7320897B1 (ja) * | 2023-05-10 | 2023-08-04 | Towa Corporation 株式会社 | 脱共役タンパク2遺伝子発現亢進用医薬組成物及び食品組成物 |
JP7397541B1 (ja) * | 2023-05-10 | 2023-12-13 | Towa Corporation 株式会社 | Nadh-ユビキノン酸化還元酵素サブユニット6遺伝子発現亢進用医薬組成物及び食品組成物 |
JP7311218B1 (ja) * | 2023-05-30 | 2023-07-19 | Towa Corporation 株式会社 | アポリポタンパク質e遺伝子発現抑制用医薬組成物及び食品組成物 |
JP7316017B1 (ja) * | 2023-05-30 | 2023-07-27 | Towa Corporation 株式会社 | セレノプロテインo遺伝子発現亢進用医薬組成物及び食品組成物 |
JP7356203B1 (ja) | 2023-08-03 | 2023-10-04 | Towa Corporation 株式会社 | WD and tetratricopeptide repeats 1遺伝子発現亢進用医薬組成物及び食品組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP2023175394A (ja) | 2023-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7134541B1 (ja) | キサンチンオキシダーゼ阻害用医薬組成物及び食品組成物 | |
JP6578046B1 (ja) | Pde5阻害用医薬組成物及びpde5阻害用食品組成物 | |
CA2734720C (en) | Hydroxybutyrate ester and medical use thereof | |
JP7253301B1 (ja) | 5-アミノレブリン酸産生促進用医薬組成物及び食品組成物 | |
EP2754444B1 (en) | Composition for improving in vivo metabolism parameter | |
JP2022158197A (ja) | 筋肥大促進用医薬組成物及び食品組成物 | |
JP7320898B1 (ja) | Fragile X mental retardation, autosomal homolog 2遺伝子発現亢進用医薬組成物及び食品組成物 | |
US20160375073A1 (en) | Composition for treatment or prevention of obesity, containing water extracts of fomitella fraxinea | |
WO2006112283A1 (ja) | 抗疲労剤 | |
WO2007066642A1 (ja) | 皮膚の乾燥予防または改善用経口剤 | |
JP5442243B2 (ja) | 腎障害抑制剤 | |
JP2010053122A (ja) | 脂質合成阻害剤 | |
EP3199037B1 (en) | Slowly-digestible long-acting energy-supplying agent | |
JP7320897B1 (ja) | 脱共役タンパク2遺伝子発現亢進用医薬組成物及び食品組成物 | |
JP7311218B1 (ja) | アポリポタンパク質e遺伝子発現抑制用医薬組成物及び食品組成物 | |
JP2009120502A (ja) | キトサン含有組成物 | |
JP7397541B1 (ja) | Nadh-ユビキノン酸化還元酵素サブユニット6遺伝子発現亢進用医薬組成物及び食品組成物 | |
JP7316017B1 (ja) | セレノプロテインo遺伝子発現亢進用医薬組成物及び食品組成物 | |
JP7356203B1 (ja) | WD and tetratricopeptide repeats 1遺伝子発現亢進用医薬組成物及び食品組成物 | |
JP7371996B1 (ja) | インスリン様成長因子2遺伝子発現亢進用医薬組成物及び食品組成物 | |
JPH0995448A (ja) | 血中ビオチン濃度の増加方法およびビオチン含有飲食品 | |
JP7370653B1 (ja) | エリスロポエチン遺伝子発現亢進用医薬組成物及び食品組成物 | |
JP2016155825A (ja) | 尿酸排泄促進組成物及びそれを用いた飲食物 | |
EP3384786B1 (en) | Use of enzyme-modified isoquercitrin | |
JP2016190801A (ja) | 難消化性グルカンを含有する血中中性脂肪上昇抑制剤および血中レムナント様リポ蛋白コレステロール上昇抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220715 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20220715 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220816 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220824 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7134541 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |